The cancer risk assessments conducted by many different regulatory authorities have changed over time with the advent of detailed mechanistic information on the involvement of PPARα in the non-genotoxic carcinogenic process, in which metabolites of DEHP activate PPARα signaling as mentioned above. This evidence concerns the gene PPARA and cancer.